February is Rare Disease Month - Support Today!
Kleefstra Syndrome is a Rare Disease and February is our month to share our stories and rally our friends and family for support!
Kleefstra Syndrome is a Rare Disease and February is our month to share our stories and rally our friends and family for support!
February is Rare Disease Month! Support TODAY!
IDefine is a nonprofit organization dedicated to discovering life-changing treatments and cures for those diagnosed with Kleefstra syndrome. Our organizational pillars are built upon supporting the caregiver community, developing and strengthening coordinated clinical care, and propelling research towards a treatment for our loved ones diagnosed with Kleefstra syndrome. Our 3 primary funding objectives of 2024 are:
- The 2024 North American Kleefstra Syndrome Family Conference outside of Boston, MA
- Funding the Kleefstra Clinic team and efforts at Boston Children's Hospital
- Developing Pre-Clinical Research Tools for researchers working on Kleefstra syndrome
What is Kleefstra Syndrome?
Kleefstra syndrome (KS) is a rare genetic disorder characterized by intellectual disability, childhood hypotonia, severe expressive speech delay and a distinctive facial appearance with a spectrum of additional clinical features. The syndrome, eponymously named for Dr. Tjitske Kleefstra, is caused by either a mutation or deletion of a gene called EHMT1 (Euchromatic Histone Methyltransferase 1). Kleefstra syndrome presents with a wide range of symptoms, and the severity of those symptoms vary from mild to severe.
IDefine, Inc. is a GA nonprofit corporation operating through a fiscal sponsorship with Players Philanthropy Fund, a Maryland charitable trust recognized by IRS as a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code (Federal Tax ID: 27-6601178, ppf.org/pp). Contributions to IDefine are tax-deductible to the fullest extent of the law.